Osaic Holdings
IKT icon

Osaic Holdings’s Inhibikase Therapeutics IKT Stock Holding History

Osaic Holdings’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,000
Closed -$6.72K – 8083
2026
Q1 		$6.72K Buy
+4,000
New +$7.1K ﹤0.01% 6520
2024
Q2 		– Sell
-2,000
Closed -$4.32K – 7508
2024
Q1 		$4.32K Buy
+2,000
New +$4.41K ﹤0.01% 6156

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Osaic Holdings's IKT Position: Q2 2026 in Review

Osaic Holdings sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 4,000 shares — an estimated $6.72K sold.

Osaic Holdings first reported a position in IKT in Q1 2024 and held it in 2 quarters. The position peaked at $6.72K in Q1 2026. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Osaic Holdings reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Osaic Holdings sold 4,000 Inhibikase Therapeutics shares in Q2 2026, an estimated $6.72K.
  • Osaic Holdings first reported a position in Inhibikase Therapeutics in Q1 2024 and held it in 2 quarters.
  • Osaic Holdings's Inhibikase Therapeutics position peaked at $6.72K in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.